DrugDashboards

Luliconazole

Luliconazole · LULICONAZOLE 10 mg/g · Cream · Topical · Oceanside Pharmaceuticals

NDC 68682-0850-60 · 1 TUBE in 1 CARTON / 60 g in 1 TUBE · NDA · View full market →

The short version

Just 2 companies supply this market — thin enough that a single exit would be felt immediately. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Pharmacies pay (NADAC)$2.68per GMinvoice-surveyed acquisition cost · Sep 18, 2024
  • Part D plans paid (avg)$3.04per dosage unitgross, before rebates — matched by drug name · 2024
  • Part D point of sale (median)$3.00per unitnegotiated price across 4 plans — before rebates · Jul 1, 2025

Medicare Part D

All Part D pricing →
ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of sale
$3.00per unit
middle half $3.00$3.00 · 4 plans · Jul 1, 2025
Est. net of rebates
$1.80–$2.25
brand drug — est. 25-40% rebate off the price at left
Coverage & restrictions
of plans cover it

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 7 quarters since 2024.

NADAC price per unit

$0$1.00$2.00$3.00May 2024Sep 2024$2.68
6 price points · per GM · last surveyed Invalid DateSource: CMS NADAC

Estimated fill cost

WAC per package, as filed
$200.00
Reported to Texas DSHS · 2026 annual filing · Bausch Health US, LLC

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicaid spend (2025)

$6,841
41 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

20Low risk

Some pressure is visible, but not much — here’s everything the score found to count.

  • 2 active manufacturers+20

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Regulatory

Application
NDA204153
TE code
Approval date
Nov 14, 2013
Patents / exclusivity
4 patents, 0 exclusivities
TypeNumber / codeExpires
patent8980931Apr 28, 2034
patent9012484Sep 6, 2033
patent9453006Sep 6, 2033
patent9199977Sep 6, 2033

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Luliconazole (Cream)

LabelerStrengthFirst seenLast seen
Bausch Health US, LLCLULICONAZOLE 10 mg/gJul 15, 2026Sep 2, 2026
Oceanside PharmaceuticalsLULICONAZOLE 10 mg/gJul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Luliconazole — NDC 68682-0850-60," retrieved September 3, 2026, https://drugdashboards.com/drug/68682085060.

Free to cite with attribution — see how the data is put together.